Invited Lecture: Restoring immune control of cancer
(2014) Symposium — Location: Beijing (China) (10.October.2014)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- In recent years, cancer immunotherapy has made tremendous progresses and reached the clinical arena by showing its ability to prolong the survival of advanced cancer patients. This has generated enormous interest in the oncology field and the pharmacological industry. Yet, the clinical benefit remains limited to a subset of patients, and further research is needed to understand the reason for this. Tumors may resist immune rejection by modulating the expression or the processing of tumor antigens. We have studied in details the processing of tumor antigens by the proteasome, and found that many antigens are processed differently by the various proteasome subtypes, so that the repertoire of antigens presented by a given tumor cell depends on its relative content in standard proteasome, immunoproteasome and intermediate proteasomes. Another key factor limiting the efficacy of cancer immunotherapy is the presence of an immunosuppressive microenvironment at the tumor site. The current challenge is therefore to understand the immunosuppressive mechanisms at work in the tumor microenvironment and to develop therapeutic strategies to overcome them. One such mechanism involves the catabolism of tryptophan by indoleamine-2,3-dioxygenase (IDO) or tryptophan dioxygenase (TDO). The resulting tryptophan shortage, combined with the production of tryptophan catabolites, is profoundly immunosuppressive, preventing the proper functioning of effector T lymphocytes and favoring regulatory T cells. IDO inhibitors are currently under clinical development. Other mechanisms involve tumor-induced apoptosis of tumor-infiltrating lymphocytes. Importantly, the immunosuppressive tumor microenvironment present in human tumors cannot be appropriately modeled using transplanted rodent tumor models, but rather requires the study of autochthonous tumor induced in genetically modified mouse models. Although such models are more difficult to study, they do better recapitulate the long-term host/tumor interactions that eventually result in immune tolerance of the growing tumor by the host. This will be illustrated using an inducible mouse melanoma model.
- Affiliations
Citations
Van den Eynde, B. (2014). Invited Lecture: Restoring immune control of cancer. Symposium, Beijing (China). https://hdl.handle.net/2078.5/49316